SBBP News and Press, Strongbridge Biopharma plc From 05/31/21

Ali Group ignites a potential bidding war for Welbilt (WBT). Cimarex Energy (XEC) and Cabot Oil & Gas Corporation (COG) combine in an $8.5 billion all-stock deal. United Rentals (UFN) completes the acquisition of General Finance Corporation (GFN) in 40 days. For further ...

Canopy set for growth on Canadian economy re-openingWhile not expecting a significant Q4 2021 beat for Canopy Growth (CGC) on June 1, MKM expects a turnaround as the Canadian economy starts to re-open.As a result, the firm is upgrading shares from neutral to buy with a C$55 price target.That ...

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “ Strongbridge Biopharma Surges after being Acquired by Xeris Pharmaceuticals ” Strongbridge Biopharma (NASDAQ: SBBP) surged over 15% ...

3 Top Penny Stocks to Watch on Monday Morning As another week of penny stock trading commences, which companies are showing momentum? Well, one of the best ways to start the week off is by making a penny stocks watchlist . This can help to organize your list of penny stocks to buy...

Creative Realities (CREX) +34%.Virgin Galactic Holdings (SPCE) +19% after successful weekend space flight.Strongbridge Biopharma (SBBP) +15% after being acquired by Xeris Pharma.Jiuzi Holdings (JZXN) +9%.Aptorum Group Limited (APM) +9% on positive interim phase I clinical trial...

Xeris Pharmaceuticals (XERS) will acquire Strongbridge Biopharma (SBBP) for stock and contingent value rights (CVRs) transaction.The agreement, including the maximum amount payable under the CVRs, values Strongbridge at ~$267M.The deal is expected to close early in Q4 2021.Upon closing, ...

Strongbridge Biopharma (SBBP) jumps 6% premarket after the FDA accepted for review Company’s New Drug Application ((NDA)) for Recorlev (levoketoconazole) for the treatment of endogenous Cushing’s syndrome.The FDA has set a PDUFA target action date of January 1, 2022, w...

~ FDA Sets Prescription Drug User Fee Act (PDUFA) Target Action Date of January 1, 2022 ~ ~ If Approved, RECORLEV® (levoketoconazole) Launch Planned for First Quarter of 2022 ~ DUBLIN, Ireland and TREVOSE, Pa., May 13, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma p...

Strongbridge Biopharma plc (SBBP) Q1 2021 Earnings Conference Call May 12, 2021, 08:30 AM ET Company Participants Lindsay Rocco - Elixir Health, Public Relations John Johnson - CEO Fredric Cohen - CMO Richard Kollender - President and CFO Scott Wilhoit - CCO Officer Conference Call Participan...

Although Strongbridge Biopharma (SBBP) saw its Q1 net loss narrow by ~7.5% to $11.8M, shares are down 1.7% in premarket trading.For Q1, the rare diseases treatment company beat estimates for EPS but missed on revenue.Sales of neuromuscular drug KEVEYIS (dichlorphenamide) rose 25% ye...